{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:52:30Z","timestamp":1790315550203,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40261-022-01138-6","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T05:04:03Z","timestamp":1647407043000},"page":"333-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2913-1867","authenticated-orcid":false,"given":"Daniel Tobias","family":"Michaeli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Stoycheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Mashudu","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6484-7161","authenticated-orcid":false,"given":"Julia Caroline","family":"Michaeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0293-9401","authenticated-orcid":false,"given":"Thomas","family":"Michaeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"1138_CR1","doi-asserted-by":"crossref","first-page":"e0190166","DOI":"10.1371\/journal.pone.0190166","volume":"13","author":"ZZA Mbulawa","year":"2018","unstructured":"Mbulawa ZZA, van Schalkwyk C, Hu N-C, Meiring TL, Barnabas S, Dabee S, et al. High human papillomavirus (HPV) prevalence in South African adolescents and young women encourages expanded HPV vaccination campaigns. PLoS ONE. 2018;13:e0190166.","journal-title":"PLoS ONE"},{"key":"1138_CR2","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359-386.","journal-title":"Int J Cancer"},{"key":"1138_CR3","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0968-8080(08)32399-4","volume":"16","author":"SL van Schalkwyk","year":"2008","unstructured":"van Schalkwyk SL, Maree JE, Wright SCD. Cervical cancer: the route from signs and symptoms to treatment in South Africa. Reprod Health Matters. 2008;16:9\u201317.","journal-title":"Reprod Health Matters"},{"key":"1138_CR4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.9745\/GHSP-D-18-00090","volume":"6","author":"S Delany-Moretlwe","year":"2018","unstructured":"Delany-Moretlwe S, Kelley KF, James S, Scorgie F, Subedar H, Dlamini NR, et al. Human papillomavirus vaccine introduction in South Africa: implementation lessons from an evaluation of the national school-based vaccination campaign. Glob Health Sci Pract. 2018;6:425\u201338.","journal-title":"Glob Health Sci Pract."},{"issue":"Suppl 3","key":"1138_CR5","doi-asserted-by":"crossref","first-page":"C28","DOI":"10.1016\/j.vaccine.2012.03.032","volume":"30","author":"MH Botha","year":"2012","unstructured":"Botha MH, Dochez C. Introducing human papillomavirus vaccines into the health system in South Africa. Vaccine. 2012;30(Suppl 3):C28-34.","journal-title":"Vaccine"},{"key":"1138_CR6","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","volume":"199","author":"DR Brown","year":"2009","unstructured":"Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years. J Infect Dis. 2009;199:926\u201335.","journal-title":"J Infect Dis"},{"key":"1138_CR7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(11)70287-X","volume":"13","author":"CM Wheeler","year":"2012","unstructured":"Wheeler CM, Castellsagu\u00e9 X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:100\u201310.","journal-title":"Lancet Oncol"},{"key":"1138_CR8","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.ygyno.2008.06.027","volume":"110","author":"D Jenkins","year":"2008","unstructured":"Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16\/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol. 2008;110:S18-25.","journal-title":"Gynecol Oncol"},{"key":"1138_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013479\/full","author":"H Bergman","year":"2019","unstructured":"Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev. 2019. https:\/\/doi.org\/10.1002\/14651858.CD013479\/full.","journal-title":"Cochrane Database Syst Rev"},{"key":"1138_CR10","doi-asserted-by":"crossref","first-page":"e0233499","DOI":"10.1371\/journal.pone.0233499","volume":"15","author":"RA Mahumud","year":"2020","unstructured":"Mahumud RA, Alam K, Keramat SA, Ormsby GM, Dunn J, Gow J. Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review. PLoS ONE. 2020;15:e0233499.","journal-title":"PLoS ONE"},{"key":"1138_CR11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/14737167.2016.1208087","volume":"17","author":"N Largeron","year":"2017","unstructured":"Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2017;17:85\u201398.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1138_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djv282","volume":"108","author":"M Brisson","year":"2016","unstructured":"Brisson M, Laprise J-F, Chesson HW, Drolet M, Malag\u00f3n T, Boily M-C, et al. Health and economic impact of switching from a 4-valent to a 9-valent HPV vaccination program in the United States. J Natl Cancer Inst. 2016;108:1\u20139.","journal-title":"J Natl Cancer Inst"},{"key":"1138_CR13","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/ijc.28541","volume":"134","author":"M Drolet","year":"2014","unstructured":"Drolet M, Laprise J-F, Boily M-C, Franco EL, Brisson M. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2014;134:2264\u20138.","journal-title":"Int J Cancer"},{"key":"1138_CR14","doi-asserted-by":"crossref","first-page":"e106836","DOI":"10.1371\/journal.pone.0106836","volume":"9","author":"S Kiatpongsan","year":"2014","unstructured":"Kiatpongsan S, Kim JJ. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries. PLoS ONE. 2014;9:e106836.","journal-title":"PLoS ONE"},{"key":"1138_CR15","doi-asserted-by":"crossref","first-page":"5753","DOI":"10.1016\/j.vaccine.2017.05.069","volume":"35","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017\u2014recommendations. Vaccine. 2017;35:5753\u20135.","journal-title":"Vaccine"},{"key":"1138_CR16","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1186\/s12879-015-1295-z","volume":"15","author":"X Li","year":"2015","unstructured":"Li X, Stander MP, Van Kriekinge G, Demarteau N. Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence. BMC Infect Dis. 2015;15:566.","journal-title":"BMC Infect Dis"},{"key":"1138_CR17","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","volume":"25","author":"M Brisson","year":"2007","unstructured":"Brisson M, Van de Velde N, De Wals P, Boily M-C. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25:5399\u2013408.","journal-title":"Vaccine"},{"key":"1138_CR18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jval.2015.08.010","volume":"18","author":"K Haeussler","year":"2015","unstructured":"Haeussler K, Marcellusi A, Mennini FS, Favato G, Picardo M, Garganese G, et al. Cost-effectiveness analysis of universal human papillomavirus vaccination using a dynamic bayesian methodology: the BEST II study. Value Health. 2015;18:956\u201368.","journal-title":"Value Health."},{"key":"1138_CR19","unstructured":"Bruni L, Albero G, Serrano B, Mena M, Collado J, G\u00f3mez D, et al. Human papillomavirus and related diseases in South Africa: Summary Report 22 October 2021. ICO\/IARC information centre on HPV and Cancer (HPV Information Centre). 2021. https:\/\/hpvcentre.net\/statistics\/reports\/ZAF.pdf. Accessed 5 Dec 2021."},{"key":"1138_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07310-y","author":"DT Michaeli","year":"2022","unstructured":"Michaeli DT, Michaeli JC, Boch T, Michaeli T. Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention in Germany. Cardiovasc Drugs Ther. 2022. https:\/\/doi.org\/10.1007\/s10557-021-07310-y.","journal-title":"Cardiovasc Drugs Ther"},{"key":"1138_CR21","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/0272989X17696997","volume":"37","author":"E Jones","year":"2017","unstructured":"Jones E, Epstein D, Garc\u00eda-Moch\u00f3n L. A procedure for deriving formulas to convert transition rates to probabilities for multistate markov models. Med Decis Making. 2017;37:779\u201389.","journal-title":"Med Decis Making"},{"key":"1138_CR22","unstructured":"Republic of South Africa. Department: Statistics South Africa. 2021. http:\/\/www.statssa.gov.za\/. Accessed 30 Nov 2021."},{"key":"1138_CR23","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.4161\/hv.29532","volume":"10","author":"PS Naud","year":"2014","unstructured":"Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16\/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccines Immunother. 2014;10:2147\u201362.","journal-title":"Hum Vaccines Immunother."},{"key":"1138_CR24","unstructured":"World Health Organization. Guidelines for estimating costs of introducing new vaccines into the national immunization system. World Health Organization. World Health Organization. 2002. https:\/\/apps.who.int\/iris\/handle\/10665\/67342. Accessed 29 Nov 2021."},{"key":"1138_CR25","first-page":"60","volume":"106","author":"I Moodley","year":"2016","unstructured":"Moodley I, Tathiah N, Sartorius B. The costs of delivering human papillomavirus vaccination to Grade 4 learners in KwaZulu-Natal, South Africa. S Afr Med J. 2016;106:60.","journal-title":"S Afr Med J"},{"key":"1138_CR26","doi-asserted-by":"crossref","first-page":"e0182663","DOI":"10.1371\/journal.pone.0182663","volume":"12","author":"S Botwright","year":"2017","unstructured":"Botwright S, Holroyd T, Nanda S, Bloem P, Griffiths UK, Sidibe A, et al. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects. PLoS ONE. 2017;12:e0182663.","journal-title":"PLoS ONE"},{"key":"1138_CR27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ygyno.2008.08.030","volume":"112","author":"A Vijayaraghavan","year":"2009","unstructured":"Vijayaraghavan A, Efrusy M, Lindeque G, Dreyer G, Santas C. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa. Gynecol Oncol. 2009;112:377\u201383.","journal-title":"Gynecol Oncol"},{"key":"1138_CR28","doi-asserted-by":"crossref","first-page":"e0177762","DOI":"10.1371\/journal.pone.0177762","volume":"12","author":"TG Ginindza","year":"2017","unstructured":"Ginindza TG, Sartorius B, Dlamini X, \u00d6stensson E. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland. PLoS ONE. 2017;12:e0177762.","journal-title":"PLoS ONE"},{"key":"1138_CR29","unstructured":"Bruni L, Albero G, Serrano B, Mena M, G\u00f3mez D, Mu\u00f1oz J, et al. Human Papillomavirus and Related Diseases in South Africa. Summary Report 17 June 2019. 2019. https:\/\/hpvcentre.net\/statistics\/reports\/ZAF.pdf?t=1572341817098. Accessed 29 Oct 2019."},{"key":"1138_CR30","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1016\/j.vaccine.2009.08.004","volume":"27","author":"E Sinanovic","year":"2009","unstructured":"Sinanovic E, Moodley J, Barone MA, Mall S, Cleary S, Harries J. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa. Vaccine. 2009;27:6196\u2013202.","journal-title":"Vaccine"},{"key":"1138_CR31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/epirev\/mxj006","volume":"28","author":"EJ Dasbach","year":"2006","unstructured":"Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev. 2006;28:88\u2013100.","journal-title":"Epidemiol Rev"},{"issue":"Suppl 1","key":"1138_CR32","doi-asserted-by":"crossref","first-page":"i49","DOI":"10.1136\/sti.2008.033324","volume":"85","author":"N McGrath","year":"2009","unstructured":"McGrath N, Nyirenda M, Hosegood V, Newell M-L. Age at first sex in rural South Africa. Sex Transm Infect. 2009;85(Suppl 1):i49-55.","journal-title":"Sex Transm Infect."},{"key":"1138_CR33","unstructured":"World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. World Health Organization. 2008. https:\/\/apps.who.int\/iris\/handle\/10665\/69981. Accessed 29 Nov 2021."},{"key":"1138_CR34","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","volume":"356","author":"FUTURE II Study Group","year":"2007","unstructured":"FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915\u201327.","journal-title":"N Engl J Med"},{"key":"1138_CR35","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","volume":"356","author":"SM Garland","year":"2007","unstructured":"Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928\u201343.","journal-title":"N Engl J Med"},{"key":"1138_CR36","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","volume":"367","author":"DM Harper","year":"2006","unstructured":"Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247\u201355.","journal-title":"Lancet"},{"key":"1138_CR37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","volume":"374","author":"J Paavonen","year":"2009","unstructured":"Paavonen J, Naud P, Salmer\u00f3n J, Wheeler CM, Chow S-N, Apter D, et al. Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301\u201314.","journal-title":"Lancet"},{"key":"1138_CR38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/1471-2458-11-203","volume":"11","author":"VJ Lee","year":"2011","unstructured":"Lee VJ, Tay SK, Teoh YL, Tok MY. Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health. 2011;11:203.","journal-title":"BMC Public Health"},{"key":"1138_CR39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1471-2334-13-75","volume":"13","author":"TA Westra","year":"2013","unstructured":"Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, et al. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infect Dis. 2013;13:75.","journal-title":"BMC Infect Dis"},{"key":"1138_CR40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2458-12-153","volume":"12","author":"J-F Shi","year":"2012","unstructured":"Shi J-F, Kang D-J, Qi S-Z, Wu H-Y, Liu Y-C, Sun L-J, et al. Impact of genital warts on health related quality of life in men and women in mainland China: a multicenter hospital-based cross-sectional study. BMC Public Health. 2012;12:153.","journal-title":"BMC Public Health"},{"key":"1138_CR41","doi-asserted-by":"crossref","first-page":"e031186","DOI":"10.1136\/bmjopen-2019-031186","volume":"9","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Ni W, Wu J. Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis. BMJ Open. 2019;9:e031186.","journal-title":"BMJ Open"},{"key":"1138_CR42","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/cncr.32003","volume":"125","author":"K Li","year":"2019","unstructured":"Li K, Li Q, Song L, Wang D, Yin R. The distribution and prevalence of human papillomavirus in women in mainland China. Cancer. 2019;125:1030\u20137.","journal-title":"Cancer"},{"key":"1138_CR43","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S1473-3099(14)70841-2","volume":"14","author":"SN Tabrizi","year":"2014","unstructured":"Tabrizi SN, Brotherton JML, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14:958\u201366.","journal-title":"Lancet Infect Dis"},{"key":"1138_CR44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.7196\/SAMJ.2018.v109i1.13723","volume":"109","author":"NJ Ngcobo","year":"2018","unstructured":"Ngcobo NJ, Burnett RJ, Cooper S, Wiysonge CS. Human papillomavirus vaccination acceptance and hesitancy in South Africa: research and policy agenda. S Afr Med J. 2018;109:13\u20135.","journal-title":"S Afr Med J"},{"key":"1138_CR45","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1097\/00002030-200111090-00011","volume":"15","author":"H Minkoff","year":"2001","unstructured":"Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS. 2001;15:2157\u201364.","journal-title":"AIDS"},{"key":"1138_CR46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eclinm.2019.08.007","volume":"15","author":"B Hansoti","year":"2019","unstructured":"Hansoti B, Mwinnyaa G, Hahn E, Rao A, Black J, Chen V, et al. Targeting the HIV epidemic in South Africa: the need for testing and linkage to care in emergency departments. EClinicalMedicine. 2019;15:14\u201322.","journal-title":"EClinicalMedicine."},{"key":"1138_CR47","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.annonc.2019.11.004","volume":"31","author":"I Kalliala","year":"2020","unstructured":"Kalliala I, Athanasiou A, Veroniki AA, Salanti G, Efthimiou O, Raftis N, et al. Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. Ann Oncol. 2020;31:213\u201327.","journal-title":"Ann Oncol"},{"key":"1138_CR48","first-page":"933","volume":"19","author":"GV Kriekinge","year":"2018","unstructured":"Kriekinge GV, Sohn W-Y, Aljunid SM, Soon R, Yong C-M, Chen J, et al. Comparative cost-effectiveness analysis of two different two-dose human papillomavirus vaccines in Malaysia. Asian Pac J Cancer Prev. 2018;19:933\u201340.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1138_CR49","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/aje\/kwk059","volume":"165","author":"N Van de Velde","year":"2007","unstructured":"Van de Velde N, Brisson M, Boily M-C. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol. 2007;165:762\u201375.","journal-title":"Am J Epidemiol"},{"key":"1138_CR50","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","volume":"9","author":"GD Sanders","year":"2003","unstructured":"Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9:37\u201348.","journal-title":"Emerg Infect Dis"},{"key":"1138_CR51","first-page":"17","volume":"15","author":"Y Kumamoto","year":"2004","unstructured":"Kumamoto Y, Tsukamoto T, Sugiyama T, Akaza H, Noguchi M, Naya A, et al. National surveillance of sexually transmitted diseases of Japan in 2002. Jpn Arch Sex Transm Dis. 2004;15:17\u201345.","journal-title":"Jpn Arch Sex Transm Dis."},{"key":"1138_CR52","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","volume":"96","author":"SJ Goldie","year":"2004","unstructured":"Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine. J Natl Cancer Inst. 2004;96:604\u201315.","journal-title":"J Natl Cancer Inst"},{"key":"1138_CR53","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1158\/1055-9965.EPI-06-0846","volume":"16","author":"RP Insinga","year":"2007","unstructured":"Insinga RP, Dasbach EJ, Elbasha EH, Liaw K-L, Barr E. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives. Cancer Epidemiol Biomarkers Prev. 2007;16:709\u201315.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1138_CR54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","volume":"13","author":"EH Elbasha","year":"2007","unstructured":"Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28\u201341.","journal-title":"Emerg Infect Dis"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01138-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01138-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01138-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T10:51:11Z","timestamp":1649328671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01138-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1138"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01138-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]},"assertion":[{"value":"23 February 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Daniel Tobias Michaeli, Sophia Stoycheva, Simon Mashudu Marcus, Wenjia Zhang, Julia Caroline Michaeli, and Thomas Michaeli declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Competing Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data are included in the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"DM: Conceptualization, methodology, investigation, formal analysis, writing \u2013 original draft, review and editing, visualization. SS: Conceptualization, methodology, investigation, writing \u2013 review and editing. SM: Conceptualization, methodology, investigation, writing \u2013 review and editing. WZ: Conceptualization, methodology, investigation, writing \u2013 review and editing. JM: Investigation, formal analysis, writing \u2013 review and editing, supervision, project management, resources. TM: Investigation, formal analysis, writing \u2013 original draft, writing \u2013 review and editing, supervision, project management, resources. All authors attest they meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}